Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis

•We modeled first-line pembrolizumab/lenvatinib(P/L) vs carboplatin/paclitaxel for advanced or recurrent endometrial cancer.•In our model, P/L improves overall survival and quality of life only in microsatellite instability-high tumors.•P/L is not cost-effective at its current price and cost would need to decrease by 85% to be cost-effective.